WebInterpretation These results suggest no overall bene t from the addition of zoledronic acid to standard adjuvant fi treatments for early breast cancer . However, zoledronic acid does reduce the development of bone metastases and, for women with established menopause, improved disease outcomes. Funding Novartis Global and NIHR Cancer Research ... Webcancer, zoledronic acid signifi cantly extended disease-free survival (n=1803 and n=1065),13,14 and clodronic acid extended overall survival in patients with metastatic …
A study of zoledronic acid for early breast cancer
WebEarly research shows that if a woman has zoledronic acid then her cancer is less likely to come back or spread to the bones. But this benefit is only seen in women who have … WebEffect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, … ble 4.0 bluetooth
Zoledronic Acid - NCI - National Cancer Institute
WebMay 9, 2024 · What is the effectiveness and cost effectiveness of different scheduling of zoledronic acid in the prevention and reduction of skeletal events in people with … WebWhat is zoledronic acid? Zoledronic acid is a drug that’s given to reduce the risk of breast cancer spreading to the bones and other parts of the body. It belongs to a group of drugs called bisphosphonates. These drugs slow down or prevent bone damage. Zoledronic acid is also prescribed: for people at risk of or who have osteoporosis WebMay 27, 2008 · Persistent circadian rhythm of bone turnover in bone metastatic breast cancer suggests greater skeletal retention of bisphosphonates if administered in the night. We assessed differential effects of night vs morning administration of zoledronic acid (ZA) on bone turnover. Forty-four breast cancer patients with bone metastases were … ble512a15s-3